{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:15:30Z","timestamp":1792091730373,"version":"4.4.0"},"reference-count":41,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp\u2019s real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.<\/jats:p>","DOI":"10.2340\/actadv.v104.41297","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:42:47Z","timestamp":1734072167000},"page":"adv41297","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study"],"prefix":"10.2340","volume":"104","author":[{"given":"Lucille","family":"Vitek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goronflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Deleuze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-B\u00e9n\u00e9dicte","family":"Duval-Modeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Fresnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Jeudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouck","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Matthieu","family":"L'Orphelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Peuvrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Quereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"86293","doi-asserted-by":"crossref","unstructured":"Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114: 2309-2315.","DOI":"10.1016\/j.ophtha.2007.01.032"},{"key":"86294","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.032","DOI":"10.1016\/j.ophtha.2007.01.032"},{"key":"86295","doi-asserted-by":"crossref","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers 2020; 6: 1-25.","DOI":"10.1038\/s41572-020-0158-0"},{"key":"86296","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41572-020-0158-0","DOI":"10.1038\/s41572-020-0158-0"},{"key":"86297","doi-asserted-by":"crossref","unstructured":"Garg G, Finger PT, Kivel\u00e4 TT, Simpson ER, Gallie BL, Saakyan S, et al. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol 2022; 106: 510-517.","DOI":"10.1136\/bjophthalmol-2020-317949"},{"key":"86298","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317949","DOI":"10.1136\/bjophthalmol-2020-317949"},{"key":"86299","doi-asserted-by":"crossref","unstructured":"Rantala ES, Hernberg M, Kivel\u00e4 TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019; 29: 561 568.","DOI":"10.1097\/CMR.0000000000000575"},{"key":"86300","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CMR.0000000000000575","DOI":"10.1097\/CMR.0000000000000575"},{"key":"86301","doi-asserted-by":"crossref","unstructured":"Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 2014; 63: 437 448.","DOI":"10.1007\/s00262-014-1525-z"},{"key":"86302","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00262-014-1525-z","DOI":"10.1007\/s00262-014-1525-z"},{"key":"86303","doi-asserted-by":"crossref","unstructured":"Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers 2019; 11: 971-987.","DOI":"10.3390\/cancers11070971"},{"key":"86304","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers11070971","DOI":"10.3390\/cancers11070971"},{"key":"86305","unstructured":"Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, et al. HLA a association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 1992; 52: 6561-6566."},{"key":"86306","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol 2022; 40: 1939 1948.","DOI":"10.1200\/JCO.21.01805"},{"key":"86307","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.21.01805","DOI":"10.1200\/JCO.21.01805"},{"key":"86308","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 2022; 28: 2364 2373.","DOI":"10.1038\/s41591-022-02015-7"},{"key":"86309","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41591-022-02015-7","DOI":"10.1038\/s41591-022-02015-7"},{"key":"86310","doi-asserted-by":"crossref","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 2021; 385: 1196 1206.","DOI":"10.1056\/NEJMoa2103485"},{"key":"86311","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2103485","DOI":"10.1056\/NEJMoa2103485"},{"key":"86312","doi-asserted-by":"crossref","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med 2023; 389: 2256-66.","DOI":"10.1056\/NEJMoa2304753"},{"key":"86313","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2304753","DOI":"10.1056\/NEJMoa2304753"},{"key":"86314","doi-asserted-by":"crossref","unstructured":"Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, et al. Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study. Cancers 2023; 15: 3430-3444.","DOI":"10.3390\/cancers15133430"},{"key":"86315","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers15133430","DOI":"10.3390\/cancers15133430"},{"key":"86316","doi-asserted-by":"crossref","unstructured":"Sullivan RJ, Milhem MM, Demidov LV, Lewis KD, Schlaak M, Piperno-Neumann S, et al. Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM). J Clin Oncol 2022; 40:16_suppl: 9585-9585.","DOI":"10.1200\/JCO.2022.40.16_suppl.9585"},{"key":"86317","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9585","DOI":"10.1200\/JCO.2022.40.16_suppl.9585"},{"key":"86318","doi-asserted-by":"crossref","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370 1380.","DOI":"10.1093\/annonc\/mdz176"},{"key":"86319","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdz176","DOI":"10.1093\/annonc\/mdz176"},{"key":"86320","doi-asserted-by":"crossref","unstructured":"Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivel\u00e4 TT. Metastatic uveal melanoma: The final frontier. Progress in Retinal and Eye Research 2022; 90: 101041-101094.","DOI":"10.1016\/j.preteyeres.2022.101041"},{"key":"86321","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101041","DOI":"10.1016\/j.preteyeres.2022.101041"},{"key":"86322","doi-asserted-by":"crossref","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol 2021; 39: 599 607.","DOI":"10.1200\/JCO.20.00605"},{"key":"86323","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.20.00605","DOI":"10.1200\/JCO.20.00605"},{"key":"86324","doi-asserted-by":"crossref","unstructured":"Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carri\u00f3n L, Mart\u00edn-Algarra S, et al. Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol 2021; 39: 586 598.","DOI":"10.1200\/JCO.20.00550"},{"key":"86325","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.20.00550","DOI":"10.1200\/JCO.20.00550"},{"key":"86326","doi-asserted-by":"crossref","unstructured":"Piulats Rodriguez JM, Piperno-Neumann S, Rutkowski P, Nathan P, Hassel JC, Espinosa E, et al. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma. Annals of Oncology 2022; 33: S924.","DOI":"10.1016\/j.annonc.2022.07.949"},{"key":"86327","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.07.949","DOI":"10.1016\/j.annonc.2022.07.949"},{"key":"86328","doi-asserted-by":"crossref","unstructured":"Petzold A, Steeb T, Wessely A, Koch EAT, Vera J, Berking C, et al. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Cancer Treat Rev 2023; 115: 102543-102551.","DOI":"10.1016\/j.ctrv.2023.102543"},{"key":"86329","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102543","DOI":"10.1016\/j.ctrv.2023.102543"},{"key":"86330","doi-asserted-by":"crossref","unstructured":"Dimitriou F, Hassel JC, Orloff M, Hughes I, Kapiteijn E, Mehmi I, et al. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1\/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Ann Oncol 2022; 33: S929.","DOI":"10.1016\/j.annonc.2022.07.958"},{"key":"86331","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.07.958","DOI":"10.1016\/j.annonc.2022.07.958"},{"key":"86332","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol 2023; 20: 99-115.","DOI":"10.1038\/s41571-022-00714-1"},{"key":"86333","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41571-022-00714-1","DOI":"10.1038\/s41571-022-00714-1"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41297\/48463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41297\/48463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:43:07Z","timestamp":1734072187000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/41297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.41297","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}